Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18799983 | COMPOSITION AND METHOD FOR TREATING HEARING LOSS | August 2024 | April 2025 | Allow | 8 | 1 | 1 | Yes | No |
| 18777570 | METHODS FOR PREPARING PRODUCTS FOR TREATING SCALD INFECTION CAUSED BY PSEUDOMONAS AERUGINOSA | July 2024 | January 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 18760549 | COMPOSITIONS AND METHODS FOR SUNLESS TANNING | July 2024 | January 2025 | Allow | 6 | 2 | 0 | Yes | No |
| 18660021 | NEW MODIFIED RELEASE ORAL CONTRACEPTIVE COMPOSITION | May 2024 | May 2025 | Allow | 12 | 2 | 0 | Yes | No |
| 18655687 | COMPOSITIONS AND DOSAGE FORMS FOR ORAL DELIVERY | May 2024 | June 2025 | Allow | 13 | 1 | 0 | Yes | No |
| 18620329 | IMPLANTABLE DEPOTS FOR THE CONTROLLED RELEASE OF THERAPEUTIC AGENTS | March 2024 | February 2025 | Allow | 11 | 1 | 0 | Yes | No |
| 18592160 | SOLID SELF-EMULSIFYING PHARMACEUTICAL COMPOSITIONS | February 2024 | March 2025 | Abandon | 13 | 1 | 0 | No | No |
| 18425556 | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer | January 2024 | April 2025 | Allow | 14 | 2 | 0 | Yes | No |
| 18576171 | USE OF A VEGETABLE EXTRACT FROM SALVIA HAENKEI AS AN ACTIVE AGENT IN THE TREATMENT OF HEART DISEASES | January 2024 | March 2025 | Allow | 14 | 2 | 0 | No | No |
| 18543854 | CROSS LINKED SILK-HYALURONIC ACID COMPOSITION | December 2023 | March 2025 | Abandon | 15 | 1 | 0 | No | No |
| 18562492 | COMPOSITION COMPRISING AN ESTER OF ALPHA-TOCOPHEROL FOR REDUCING THE RISK OF PRETERM BIRTH | November 2023 | July 2025 | Allow | 19 | 4 | 0 | Yes | No |
| 18467953 | METHODS OF TREATING ENDOMETRIAL CANCER USING HEMP EXTRACT | September 2023 | November 2024 | Allow | 14 | 1 | 0 | Yes | No |
| 18240488 | ANTIMICROBIAL BANDAGE | August 2023 | December 2024 | Allow | 16 | 2 | 0 | Yes | No |
| 18351711 | Treatment of Epithelial Cysts by Intracystic Injection of Antineoplastic Particles | July 2023 | August 2024 | Allow | 13 | 1 | 0 | Yes | No |
| 18265903 | ANTI-OBESITY POTENTIAL OF BISDEMETHOXYCURCUMIN COMPOSITIONS | June 2023 | February 2025 | Abandon | 20 | 1 | 0 | No | No |
| 18200980 | BENDAMUSTINE PHARMACEUTICAL COMPOSITIONS | May 2023 | July 2024 | Abandon | 14 | 1 | 0 | No | No |
| 18319948 | TOPICAL TREATMENT FOR ANIMALS | May 2023 | August 2024 | Abandon | 15 | 0 | 1 | No | No |
| 18305051 | METHODS FOR FABRICATING ISOLATED MICRO- OR NANO-STRUCTURES USING SOFT OR IMPRINT LITHOGRAPHY | April 2023 | May 2024 | Abandon | 13 | 1 | 0 | No | No |
| 18295670 | PHARMACEUTICAL FORMULATION | April 2023 | May 2024 | Allow | 13 | 1 | 0 | Yes | No |
| 18021165 | NEW MODIFIED RELEASE ORAL CONTRACEPTIVE COMPOSITION | February 2023 | May 2025 | Allow | 27 | 2 | 0 | Yes | No |
| 18154419 | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer | January 2023 | November 2023 | Allow | 10 | 1 | 0 | Yes | No |
| 18082275 | Compositions for the Treatment of Dry Eye and Methods of Use Thereof | December 2022 | February 2025 | Abandon | 26 | 2 | 1 | Yes | No |
| 18059270 | THERAPEUTIC COMPOUNDS, FORMULATIONS, AND USES THEREOF | November 2022 | April 2024 | Allow | 16 | 1 | 0 | No | No |
| 18070021 | Self-Neutralizing Amino Acid Based Cationic Compositions | November 2022 | November 2024 | Allow | 23 | 3 | 0 | Yes | No |
| 17984001 | COMPOSITIONS AND METHODS OF ADMINISTERING BACLOFEN | November 2022 | February 2024 | Allow | 15 | 1 | 0 | Yes | No |
| 18050021 | METHODS OF TREATING ENDOMETRIAL CANCER USING HEMP EXTRACT | October 2022 | September 2023 | Allow | 10 | 1 | 1 | Yes | No |
| 17966916 | Composition and method of treatment of elevated ApoE gene expression related health issues | October 2022 | February 2023 | Allow | 4 | 1 | 1 | Yes | No |
| 17966901 | Composition and method of treatment of health issues related to estrogen metabolism with elevated risk factors in females | October 2022 | February 2023 | Allow | 4 | 1 | 1 | Yes | No |
| 18046002 | Treatment of Epithelial Cysts by Intracystic Injection of Antineoplastic Particles | October 2022 | June 2023 | Allow | 8 | 1 | 0 | No | No |
| 17917774 | LOW ENDOTOXIN GELATIN-(METH)ACRYLOYL | October 2022 | April 2025 | Allow | 30 | 1 | 1 | Yes | No |
| 17942396 | METHOD OF IDENTIFYING AND TREATING PREMATURE INFANTS AT RISK FOR BPD | September 2022 | January 2024 | Allow | 17 | 1 | 0 | Yes | No |
| 17823020 | COMPOSITIONS AND METHODS FOR ENHANCING THE EFFICACY OF CONTRACEPTIVE MICROBICIDES | August 2022 | March 2024 | Allow | 19 | 1 | 0 | No | No |
| 17812479 | Lapatinib particles and uses thereof | July 2022 | January 2024 | Allow | 18 | 2 | 1 | Yes | No |
| 17784575 | MINERAL SUPPLEMENTS FOR RUMINANT NUTRITION | June 2022 | March 2025 | Allow | 33 | 2 | 1 | No | No |
| 17745923 | Pouches Comprising Oral Care Active Agents | May 2022 | April 2024 | Abandon | 23 | 3 | 0 | No | No |
| 17738803 | THERAPEUTIC COMPOSITIONS FOR TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS | May 2022 | April 2023 | Allow | 11 | 1 | 0 | No | No |
| 17719912 | ELECTRONIC VAPOR LIQUID COMPOSITION AND METHOD OF USE IN A DISPENSER | April 2022 | September 2024 | Abandon | 29 | 4 | 1 | Yes | No |
| 17713069 | CROSS LINKED SILK-HYALURONIC ACID COMPOSITION | April 2022 | December 2023 | Abandon | 21 | 2 | 0 | No | No |
| 17703955 | COMBINATION OF 25-HYDROXYVITAMIN D AND ANTIOXIDANTS/ANTI-INFLAMMATORIES FOR POULTRY OVARIAN HEALTH | March 2022 | March 2024 | Allow | 24 | 3 | 0 | No | No |
| 17685830 | PHARMACEUTICAL COMPOSITIONS OF PIMOBENDAN | March 2022 | September 2024 | Allow | 31 | 4 | 0 | Yes | No |
| 17680970 | COMPOSITION FOR TREATMENT OF TOPICAL DERMATOLOGICAL BACTERIAL SKIN CONDITIONS | February 2022 | August 2024 | Allow | 29 | 1 | 0 | No | No |
| 17628191 | ANTI-COCCIDIAL PHYTOGENIC FORMULATIONS | January 2022 | May 2025 | Abandon | 40 | 2 | 0 | No | No |
| 17596647 | PROTEIN-MODIFIED PLGA MICROSPHERE AND TISSUE-ENGINEERED NERVE CONSTRUCTED THEREWITH | December 2021 | August 2023 | Allow | 20 | 2 | 0 | Yes | No |
| 17644069 | CENTRAL NERVOUS SYSTEM HEALTH SUPPLEMENT | December 2021 | May 2025 | Allow | 41 | 1 | 0 | No | No |
| 17546640 | EDDS CHELATED NANOCERIA WITH CATALASE-LIKE ACTIVITY | December 2021 | May 2023 | Allow | 17 | 1 | 0 | Yes | No |
| 17540695 | KETAMINE TRANSDERMAL DELIVERY SYSTEM | December 2021 | February 2024 | Abandon | 26 | 1 | 0 | No | No |
| 17532874 | BENDAMUSTINE PHARMACEUTICAL COMPOSITIONS | November 2021 | March 2023 | Allow | 15 | 1 | 0 | Yes | No |
| 17612100 | CANNABINOID-COMPRISING COMPOSITIONS FOR MANAGEMENT OF PAIN | November 2021 | May 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17525298 | COMPOSITIONS AND METHODS OF ADMINISTERING BACLOFEN | November 2021 | August 2022 | Allow | 9 | 2 | 0 | No | No |
| 17454320 | IMPLANTABLE DEPOTS FOR THE CONTROLLED RELEASE OF THERAPEUTIC AGENTS | November 2021 | March 2024 | Allow | 28 | 1 | 0 | Yes | No |
| 17595019 | ANTI-CANCER GOLD COMPOUNDS | November 2021 | September 2024 | Allow | 34 | 1 | 0 | No | No |
| 17604133 | NON-AQUEOUS DRIFT CONTROL SUSPENSIONS | October 2021 | July 2025 | Allow | 45 | 2 | 1 | Yes | No |
| 17499648 | METHODS FOR TREATING CHEMORESISTANT CANCER-INITIATING CELLS | October 2021 | April 2024 | Abandon | 30 | 0 | 1 | No | No |
| 17497819 | HIGHLY TRANSPARENT WATER CONTINUOUS DENSE NANOLIPID FLUID (DNLF) DISPERSIONS AND METHOD OF PREPARATION USING A TWIN SCREW EXTRUDER | October 2021 | December 2024 | Allow | 38 | 3 | 1 | Yes | No |
| 17480948 | COMPOSITIONS AND METHODS FOR DECREASING, OR PREVENTING OR REVERSING GAIN OF, SKIN PIGMENTATION IN A MAMMALIAN SUBJECT | September 2021 | December 2023 | Allow | 27 | 2 | 0 | Yes | No |
| 17472819 | NANOPARTICLES CARRYING ANTIBIOTICS | September 2021 | November 2023 | Allow | 26 | 1 | 0 | No | No |
| 17471475 | ELECTRONIC VAPOR LIQUID COMPOSITION AND METHOD OF USE | September 2021 | March 2023 | Abandon | 18 | 0 | 1 | No | No |
| 17461713 | Methods for the preparation of biologically active compounds in nanoparticulate form | August 2021 | December 2023 | Abandon | 28 | 1 | 1 | No | No |
| 17432840 | METHODS AND USES OF NATURAL BASED COMPOSITIONS | August 2021 | November 2024 | Abandon | 39 | 0 | 1 | No | No |
| 17432904 | SAFE PARTICLES FOR THE INTRODUCTION OF USEFUL CHEMICAL AGENTS IN THE BODY WITH CONTROLLED ACTIVATION | August 2021 | January 2024 | Abandon | 29 | 0 | 1 | No | No |
| 17401178 | SYSTEMS AND METHODS FOR FEEDING SUGAR ALCOHOL TO RUMINANTS DURING PERIODS OF HEAT STRESS | August 2021 | January 2023 | Allow | 17 | 1 | 0 | Yes | No |
| 17381786 | Lapatinib particles and uses thereof | July 2021 | July 2022 | Abandon | 12 | 1 | 1 | No | No |
| 17422958 | SKIN ENGAGING MEMBER FOR RAZOR CARTRIDGE | July 2021 | February 2025 | Abandon | 43 | 3 | 1 | No | No |
| 17373496 | METHODS AND COMPOSITIONS USING PEPTIDES AND PROTEINS WITH C-TERMINAL ELEMENTS | July 2021 | December 2024 | Allow | 41 | 3 | 0 | Yes | Yes |
| 17363061 | DENTAL DESENSITIZER | June 2021 | March 2024 | Allow | 33 | 0 | 0 | Yes | No |
| 17305009 | THERAPEUTIC COMPOUNDS, FORMULATIONS, AND USES THEREOF | June 2021 | September 2022 | Allow | 15 | 0 | 0 | Yes | No |
| 17362129 | OMEGA-3 FATTY ACID ESTER COMPOSITIONS | June 2021 | April 2023 | Abandon | 21 | 1 | 0 | No | No |
| 17343900 | ORAL DOSAGE FORMS OF IBRUTINIB | June 2021 | March 2022 | Allow | 9 | 1 | 0 | Yes | No |
| 17333629 | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer | May 2021 | September 2022 | Allow | 16 | 0 | 0 | Yes | No |
| 17315804 | Treatment of Epithelial Cysts by Intracystic Injection of Antineoplastic Particles | May 2021 | September 2022 | Allow | 16 | 0 | 0 | Yes | No |
| 17242030 | DISCONTINUOUS GUMMY DELIVERY SYSTEMS | April 2021 | November 2024 | Abandon | 43 | 4 | 1 | Yes | No |
| 17288310 | COMPOSITION THAT FORMS LIQUID CRYSTALLINE PARTICLES | April 2021 | September 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17236055 | ANTIMICROBIAL AGENT | April 2021 | February 2023 | Allow | 22 | 1 | 0 | No | No |
| 17286396 | METHODS FOR TREATING A SUBTYPE OF SMALL CELL LUNG CANCER | April 2021 | January 2025 | Abandon | 45 | 1 | 1 | No | No |
| 17225218 | Structured Rheological Solid Personal Care Composition | April 2021 | December 2024 | Abandon | 45 | 4 | 1 | No | No |
| 17279551 | NANO-LIPID CARRIER FOR ENCAPSULATION OF BIOACTIVE MATERIAL, AND METHOD FOR PRODUCING SAME | March 2021 | September 2023 | Allow | 30 | 2 | 1 | Yes | No |
| 17279067 | LIPID BARRIER REPAIR | March 2021 | February 2024 | Allow | 35 | 3 | 0 | Yes | No |
| 17203639 | THERAPEUTIC COMPOUNDS, FORMULATIONS, AND USES THEREOF | March 2021 | May 2021 | Allow | 2 | 0 | 0 | Yes | No |
| 17275665 | Capsule, Tablet or Pill | March 2021 | August 2022 | Abandon | 17 | 1 | 0 | No | No |
| 17190628 | MEDICAL GELS CONTAINING A QUATERNARY AMMONIUM COMPOUND, PHENOXYETHANOL, ALOE VERA JUICE, AND NATURAL SPORICIDAL MOISTURIZERS | March 2021 | February 2023 | Abandon | 24 | 1 | 0 | No | No |
| 17189973 | MOLECULAR HYDROGEN-CONTAINING COMPOSITION FOR PREVENTION AND/OR IMPROVEMENT OF GENETIC DISORDER | March 2021 | March 2023 | Abandon | 24 | 1 | 0 | No | No |
| 17186442 | PDE9 INHIBITORS FOR TREATING SICKLE CELL DISEASE | February 2021 | September 2024 | Allow | 43 | 1 | 1 | No | No |
| 17181671 | ELECTROSPUN STRUCTURES HAVING A PHARMACEUTICAL AND METHODS OF MAKING AND USING THE SAME | February 2021 | August 2023 | Abandon | 30 | 2 | 1 | No | No |
| 17248949 | IMPLANTABLE DEPOTS FOR THE CONTROLLED RELEASE OF THERAPEUTIC AGENTS | February 2021 | October 2021 | Allow | 8 | 2 | 0 | Yes | No |
| 17170231 | Composition and Method for Transdermal Delivery of Cannabidiol (CBD) and 9-Tetrahydrocannabinol (THC) | February 2021 | July 2022 | Allow | 17 | 2 | 1 | Yes | No |
| 17264046 | SOLID ORAL FORMULATIONS OF AMPHOTERICIN B | January 2021 | July 2022 | Abandon | 17 | 1 | 0 | No | No |
| 17263645 | SOLID SELF-EMULSIFYING PHARMACEUTICAL COMPOSITIONS | January 2021 | March 2024 | Abandon | 37 | 3 | 0 | Yes | No |
| 17150038 | INJECTABLE COMPOSITE INKS AND METHODS FOR MAKING AND USING THEREOF | January 2021 | December 2023 | Allow | 35 | 2 | 0 | No | No |
| 17259325 | FORMULATION OF CANNABINOID COMPOUNDS | January 2021 | September 2024 | Abandon | 44 | 0 | 1 | No | No |
| 17257940 | TREATMENT AND PREVENTION OF INJURY DUE TO RADIATION EXPOSURE | January 2021 | June 2023 | Allow | 29 | 2 | 0 | Yes | No |
| 17129519 | Liquid Micro-Dosing Product Containing an Effective Amount of Cannabis and Process for Making the Same | December 2020 | April 2023 | Abandon | 27 | 0 | 1 | No | No |
| 17104170 | MACROMOLECULAR SYSTEM FOR DELIVERY OF EXOGENOUS ACTIVE SUBSTANCES WITH IMMUNE TRAP TO AVOID NEUTRALIZATION THEREOF | November 2020 | February 2023 | Abandon | 27 | 0 | 1 | No | No |
| 17102125 | IMPLANTABLE DRUG ELUTING SYSTEM AND METHOD OF USE | November 2020 | August 2024 | Abandon | 44 | 8 | 1 | Yes | No |
| 16952139 | AND IMPROVED SKINCARE PRODUCTS | November 2020 | March 2025 | Abandon | 52 | 2 | 1 | No | No |
| 17057093 | PHARMACEUTICAL COMPOSITION OF TAMSULOSIN AND DUTASTERIDE | November 2020 | June 2023 | Allow | 31 | 3 | 1 | Yes | No |
| 16951996 | MICRONUTRIENT SUPPLEMENTS | November 2020 | December 2024 | Abandon | 49 | 3 | 0 | No | Yes |
| 17097039 | PHARMACEUTICAL COMPOSITIONS OF PIMOBENDAN | November 2020 | December 2021 | Allow | 13 | 0 | 0 | No | No |
| 17095301 | METHODS FOR FABRICATING ISOLATED MICRO- OR NANO-STRUCTURES USING SOFT OR IMPRINT LITHOGRAPHY | November 2020 | December 2022 | Allow | 25 | 2 | 0 | Yes | No |
| 17054272 | COMPOSITIONS AND DOSAGE FORMS FOR ORAL DELIVERY | November 2020 | February 2024 | Allow | 39 | 3 | 0 | No | Yes |
| 17092150 | TOPICAL TREATMENT FOR ANIMALS | November 2020 | January 2023 | Allow | 27 | 1 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner WORSHAM, JESSICA N.
With a 29.4% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 25.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner WORSHAM, JESSICA N works in Art Unit 1615 and has examined 719 patent applications in our dataset. With an allowance rate of 56.5%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 29 months.
Examiner WORSHAM, JESSICA N's allowance rate of 56.5% places them in the 11% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by WORSHAM, JESSICA N receive 2.44 office actions before reaching final disposition. This places the examiner in the 83% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by WORSHAM, JESSICA N is 29 months. This places the examiner in the 44% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +60.7% benefit to allowance rate for applications examined by WORSHAM, JESSICA N. This interview benefit is in the 97% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 17.2% of applications are subsequently allowed. This success rate is in the 8% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 38.9% of cases where such amendments are filed. This entry rate is in the 52% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 121.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 82% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 77.0% of appeals filed. This is in the 64% percentile among all examiners. Of these withdrawals, 57.9% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 49.4% are granted (fully or in part). This grant rate is in the 59% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 0.4% of allowed cases (in the 58% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 0% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.